Emergent Biodefense Operations Lansing LLCSeptember 29, 2021

FDA 483 - Emergent Biodefense Operations Lansing LLC - September 29, 2021

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Emergent Biodefense Operations Lansing LLC

Record Details

An FDA inspection of Emergent BioDefense Operations Lansing LLC in Lansing, MI, revealed that the firm's reserve drug product samples were not representative of each lot or batch. This issue stemmed from an inadequate sample collection plan and a deficient standard operating procedure (SOP) for retention sampling. The firm failed to collect samples throughout the entire production lot for products like BioThrax® and AV7909.

Company: Emergent Biodefense Operations Lansing LLC
Inspection Date: September 29, 2021
Product Type: Biologics
Office: Division of Pharmaceutical Quality Operations III
People: Brantley S. Collins (investigator)
Linda Thai (Team Biologics Staff)

Open in Dashboard

ID · 897aede3-ab80-4bab-86b4-583db5c1bc99